MBX Biosciences Files Proxy Materials
Ticker: MBX · Form: DEFA14A · Filed: Apr 22, 2026 · CIK: 0001776111
Sentiment: neutral
Topics: proxy-filing, sec-filing, pharmaceuticals
TL;DR
MBX Biosciences dropped proxy materials on 4/22/26 - shareholders need to review.
AI Summary
MBX Biosciences, Inc. filed a DEFA14A on April 22, 2026, related to additional definitive proxy soliciting materials. The filing includes the main DEFA14A document along with two graphic files, likely containing visual information for shareholders. The company is based in Carmel, Indiana, and operates in the Pharmaceutical Preparations sector.
Why It Matters
This filing provides shareholders with important information and materials related to proxy solicitations, which are crucial for voting on company matters.
Risk Assessment
Risk Level: low — This is a routine proxy filing and does not indicate any immediate financial or operational risks.
Key Players & Entities
- MBX Biosciences, Inc. (company) — Filer of the DEFA14A
- 0001776111 (company) — CIK number for MBX Biosciences, Inc.
- 2026-04-22 (date) — Filing date of the DEFA14A
FAQ
What is the purpose of a DEFA14A filing?
A DEFA14A filing is used to provide additional definitive proxy soliciting materials and Rule 14(a)(12) material to shareholders.
When was this DEFA14A filing accepted by the SEC?
The DEFA14A filing was accepted on 2026-04-22 at 08:05:46.
What is the CIK number for MBX Biosciences, Inc.?
The CIK number for MBX Biosciences, Inc. is 0001776111.
What is the primary business sector of MBX Biosciences, Inc.?
MBX Biosciences, Inc. operates in the Pharmaceutical Preparations sector (SIC code 2834).
Where is MBX Biosciences, Inc. located?
MBX Biosciences, Inc. has its mailing and business address at 11711 N. MERIDIAN STREET SUITE 300 CARMEL IN 46032.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 22, 2026 regarding MBX Biosciences, Inc. (MBX).